Skip to Content

Generic Juxtapid Availability

Juxtapid is a brand name of lomitapide, approved by the FDA in the following formulation(s):

JUXTAPID (lomitapide mesylate - capsule;oral)

  • Manufacturer: AEGERION
    Approval date: December 21, 2012
    Strength(s): EQ 5MG BASE, EQ 10MG BASE, EQ 20MG BASE
  • Manufacturer: AEGERION
    Approval date: April 23, 2015
    Strength(s): EQ 30MG BASE, EQ 40MG BASE, EQ 60MG BASE [RLD]

Has a generic version of Juxtapid been approved?

No. There is currently no therapeutically equivalent version of Juxtapid available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Juxtapid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Inhibitors of microsomal triglyceride transfer protein and method
    Patent 5,712,279
    Issued: January 27, 1998
    Inventor(s): Biller; Scott A. & Dickson; John K. & Lawrence; R. Michael & Magnin; David R. & Poss; Michael A. & Robl; Jeffrey A. & Sulsky; Richard B. & Tino; Joseph A.
    Assignee(s): Bristol-Myers Squibb Company
    Compounds are provided which inhibit microsomal triglyceride transfer protein and thus are useful for lowering serum lipids and treating atherosclerosis and related diseases. The compounds have the structure ##STR1## wherein Z, X.sup.1, X.sup.2, x and R.sup.5 are as defined herein.
    Patent expiration dates:
    • February 21, 2020
      ✓ 
      Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Microsomal triglyceride transfer protein
    Patent 6,492,365
    Issued: December 10, 2002
    Inventor(s): John R.; Wetterau, II & Daru Young; Sharp & Richard E.; Gregg
    Assignee(s): Bristol-Myers Squibb Company
    Nucleic acid sequences, particularly DNA sequences, coding for all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, expression vectors containing the DNA sequences, host cells containing the expression vectors, and methods utilizing these materials. The invention also concerns polypeptide molecules comprising all or part of the high molecular weight subunit of microsomal triglyceride transfer protein, and methods for producing these polypeptide molecules. The invention additionally concerns novel methods for preventing, stabilizing or causing regression of atherosclerosis and therapeutic agents having such activity. The invention concerns further novel methods for lowering serum liquid levels and therapeutic agents having such activity.
    Patent expiration dates:
    • December 10, 2019
      ✓ 
      Patent use: TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
  • Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
    Patent 7,932,268
    Issued: April 26, 2011
    Inventor(s): Rader; Daniel J.
    Assignee(s): The Trustees of the University of Pennsylvania
    The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Patent expiration dates:
    • August 19, 2027
      ✓ 
      Patent use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
  • Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
    Patent 8,618,135
    Issued: December 31, 2013
    Assignee(s): The Trustees of the University of Pennsylvania
    The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Patent expiration dates:
    • March 7, 2025
      ✓ 
      Patent use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
  • Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
    Patent 9,265,758
    Issued: February 23, 2016
    Assignee(s): The Trustees of the University of Pennsylvania
    The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Patent expiration dates:
    • March 7, 2025
      ✓ 
      Patent use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
  • Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
    Patent 9,364,470
    Issued: June 14, 2016
    Assignee(s): The Trustees of the University of Pennsylvania
    The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Patent expiration dates:
    • March 7, 2025
      ✓ 
      Patent use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
  • Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
    Patent 9,433,617
    Issued: September 6, 2016
    Assignee(s): The Trustees of the University of Pennsylvania
    The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
    Patent expiration dates:
    • March 7, 2025
      ✓ 
      Patent use: A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • December 21, 2017 - NEW CHEMICAL ENTITY
    • December 21, 2019 - ORPHAN DRUG EXCLUSIVITY

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide